For Authors|For Editors|For Reviewers

Collections

Molecular Mechanisms and Biomarkers in Multiple Myeloma and Lymphoma
Editor: Francesco Gaudio and Stefano Martinotti

Submission Deadline: 30 November 2025 (Status: Open)


Special Issue Editor(s)


Prof. Francesco Gaudio      Email   |   Website
Unit of Hematology, Department of Medicine, Miulli General Hospital, LUM University, Acquaviva delle Fonti (BA), Italy
Interests: lymphoma; stem cell transplantation; bone marrow transplantation; hematologic diseases; clinical hematology; flow cytometry



Prof. Stefano Martinotti      Email   |   Website
Unit of Clinical Pathology and Microbiology, Department of Medicine, Miulli General Hospital, LUM University, Acquaviva delle Fonti (BA), Italy
Interests: cell culture; cell signaling; cancer biology; western blot analysis; PCR; immunofluorescence


Special Issue Information

Dear Colleagues,

This special issue aims to explore the molecular mechanisms and biomarkers associated with multiple myeloma and lymphoma—the two hematological malignancies that are prevalent worldwide. Both diseases, while distinct in their clinical presentation and therapeutic strategies, share common molecular pathways that contribute to their development, progression, and treatment resistance. Understanding these mechanisms is crucial for advancing diagnostic approaches and identifying novel therapeutic targets. The issue will highlight recent innovations in molecular biology, focusing on the genetic and epigenetic alterations that drive tumorigenesis in both multiple myeloma and lymphoma. It will also examine the role of biomarkers in disease monitoring, prognosis, and therapy selection, emphasizing their potential to guide personalized medicine. In addition, research works exploring emerging therapeutic approaches, including targeted therapies, immunotherapies such as CAR-T cells, and combination treatments, in relation to the two malignancies of interest are welcomed. The goal of this special issue is to provide a comprehensive overview of the current state of research and to identify promising directions for future studies that may lead to more effective treatments and improved patient outcomes. By bringing together cutting-edge research on molecular mechanisms, biomarkers, and innovative therapies, this special issue seeks to contribute to a deeper understanding of these complex diseases and the development of more precise, individualized treatment strategies.

Prof. Francesco Gaudio and Prof. Stefano Martinotti
Guest Editors


Keywords

molecular mechanisms; biomarkers; multiple myeloma; lymphoma; therapeutic approaches; targeted therapy; immunotherapy; precision medicine


Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://www.discovmed.com/Journalx_dm/authorLogOn.action by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. Submitted manuscripts should be well formatted in good English.

Journal
Publication year
Channels
Sort by Default Latest Most read  
Please wait a minute...
  • Select all
    |
  • Review
    Cameron Van Cleave, Brendan H. Saunders, Giada Bianchi
    Discovery Medicine. 2025, 37(201): 2072-2088. https://doi.org/10.24976/Discov.Med.202537201.178

    Multiple myeloma (MM) is a hematological disease that remains largely incurable. The introduction of proteasome inhibitors (PIs) at the turn of the century led to prolonged survival of patients, though most will inevitably develop resistance over successive treatments. It is of great clinical interest, then, to resensitize MM cells to PIs. This review discusses some of the most well-established resistance pathways, such as alterations in the proteostasis network and the bone marrow microenvironment. Novel targets are highlighted and placed in the context of potential treatment strategies where applicable.

  • Review
    Flavia Carbone, Bruna Daraia, Clorinda Maria Luisa Derosa, Pamela Pinto, Angela Maria Moramarco, Giuseppe Lenoci, Claudia Denapoli, Amanda Caruso, Francesco Gaudio, Stefano Martinotti
    Discovery Medicine. 2025, 37(200): 1745-1754. https://doi.org/10.24976/Discov.Med.202537200.151

    Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells, leading to organ damage and symptoms summarized by the acronym CRAB (calcium elevation, renal insufficiency, anemia, and bone lesions). The disease can also present with extramedullary involvement, which signifies a more aggressive course and may affect various organs such as the skin, liver, kidneys, and central nervous system. MM progresses from precursor stages like monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), which differ in their risk of progression to active disease. Genetic alterations—including chromosomal translocations, deletions, amplifications, and point mutations—are central to pathogenesis and may influence prognosis and therapeutic response in MM. This review explores the genetic changes that drive MM progression, their prognostic implications, and the role of advanced diagnostic technologies in improving risk stratification and guiding personalized treatment. In particular, we examine key genetic alterations such as t(4;14), del(17p), and cellular myelocytomatosis oncogene (c-MYC) amplification, and their influence on treatment outcomes. The review also highlights recent advancements in diagnostic techniques, including next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR), which are transforming MM management through more precise and targeted therapeutic strategies. The integration of these diagnostic tools promises to enhance personalized treatment approaches, leading to improved outcomes and survival by tailoring therapies to each patient's genetic profile.